Synopsis of recent research by authors named "Yi-Jung Huang"
Yi-Jung Huang's research primarily focuses on enhancing the therapeutic efficacy and safety of cancer treatments, notably through the use of immune checkpoint inhibitors and the exploration of various drug inhibitors against viral infections, such as Zika and dengue viruses.!
Recent studies highlight the development of novel protease inhibitors that show promise in treating viral diseases and the utilization of XPF-ERCC1 blockers to improve chemoradiotherapy outcomes in colorectal cancer, indicating a versatile approach to different oncological and virological challenges.!
Huang has also investigated the effects of biological factors, such as hyperglycemia and ERCC1 overexpression, on treatment resistance in cancer therapies, emphasizing the need to tailor treatment strategies based on individual patient profiles for better clinical outcomes.!